Search Login Register

4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide (nilotinib) Summary

Description: antineoplastic agent; structure in first source

Also Known As: nilotinib; AMN107

Networked: 523 relevant articles (69 outcomes, 86 trials/studies) for this Drug

Key Diseases for which 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide is Relevant

  1. BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) : 36 outcomes 43 studies in 313 results
  2. Philadelphia Chromosome : 9 outcomes 17 studies in 59 results
  3. Leukemia : 9 outcomes 3 studies in 42 results
  4. Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) : 5 outcomes 8 studies in 25 results
  5. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) : 4 outcomes 8 studies in 24 results
Show All >>

Drugs Related to 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

  1. imatinib (Gleevec)
  2. dasatinib (BMS 354825)
  3. Protein-Tyrosine Kinases (Tyrosine Kinase)
  4. Phosphotransferases (Kinase)
  5. 4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
  6. sunitinib (Sutent)
  7. Bcr-Abl tyrosine kinase
  8. sorafenib (BAY 43-9006)
  9. Doxorubicin (Adriamycin)
  10. Glucose-6-Phosphate Isomerase (Phosphoglucose Isomerase)
Show All >>

Therapies Related to 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

  1. Stem Cell Transplantation
  2. Heterologous Transplantation (Xenotransplantation)
  3. Transplants (Transplant)
  4. Hematopoietic Stem Cell Transplantation
  5. Transplantation (Transplant Recipients)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.